Moderna, Inc. Share-based Payment Arrangement, Decrease for Tax Withholding Obligation
Moderna, Inc. (MRNA) reported Share-based Payment Arrangement, Decrease for Tax Withholding Obligation of $2.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Notes › Equity
us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-07-31
- Moderna, Inc. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2026-06-30 was $2.00M.
- Moderna, Inc. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2026-03-31 was $2.00M, a 100.00% increase year-over-year.
- Moderna, Inc. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2025-03-31 was $1.00M.
- Moderna, Inc. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2025 was $2.00M.
| Period end | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 3 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 6 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 12 month |
|---|---|---|---|
| 2026-06-30 | $2.00M 10-Q · filed 2026-07-31 | $4.00M derived: sum of 2 quarters · filed 2026-07-31 | |
| 2026-03-31 | $2.00M 10-Q · filed 2026-05-01 | ||
| 2025-12-31 | $2.00M 10-K · filed 2026-02-20 | ||
| 2025-03-31 | $1.00M 10-Q · filed 2026-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |